A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus
American Journal of Nephrology Dec 22, 2017
Mathur VS, et al. - Nalbuphine extended-release tablets were tested as a treatment option for hemodialysis patients with moderate or severe uremic pruritus, in this largest-to-date randomized controlled trial. A durable and significantly reduced itching intensity was reported in those treated with nalbuphine extended-release tablets 120 mg.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
